Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study.

Abstract:

BACKGROUND:NSAIDs are widely used to treat fever and pain in children, but their possible role in the progression of some bacterial infections is controversial. OBJECTIVE:This study was performed to analyse reported cases of severe bacterial infection associated with NSAID exposure in children admitted for this reason to a general paediatric department. METHODS:This study was based on the reporting system of hospital admissions for severe bacterial infections in children after NSAID exposure, and followed the recommendations of the European Guidelines of Pharmacovigilance for medicines used in a paediatric population. Data were prospectively collected and reported by active daily surveillance in the department from November 2002 to November 2005. RESULTS:Thirty-two cases of severe bacterial infections (cellulitis, soft tissue abscesses, parapneumonic empyema, necrotizing pneumonia, adenophlegmon [fever and a tender, warm and easily compressible neck mass] and lateral or retropharyngeal abscesses) were identified in children who had received NSAIDs, principally ibuprofen, in an exposure window of 15 days before the beginning of the signs of infection. Staphylococcus aureus, group A streptococci and Streptococcus pneumoniae were identified. Seven (22%) children required surgical treatment, and four (13%) were hospitalized in an intensive care unit. CONCLUSIONS:The frequency of hospitalization for severe bacterial infection as a possible adverse effect of NSAID use was 0.6% (95% CI 0.4, 0.9) of all admissions during the study period. The frequency of severe bacterial infections after exposure to NSAIDs was elevated (one case per month) in the department studied. Further work is necessary to confirm these findings, given the potential for recruitment and protopathic biases in our study.

journal_name

Clin Drug Investig

authors

Leroy S,Marc E,Bavoux F,Tréluyer JM,Gendrel D,Bréart G,Pons G,Chalumeau M

doi

10.2165/11532890-000000000-00000

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

179-85

issue

3

eissn

1173-2563

issn

1179-1918

pii

4

journal_volume

30

pub_type

杂志文章
  • Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.

    abstract:BACKGROUND AND OBJECTIVE:Injectable collagenase Clostridium histolyticum is efficacious in correcting Dupuytren's contracture as assessed by changes in the angle of contracture and range of motion (ROM). However, clinically important changes in ROM have not been evaluated in depth. The objective of this secondary analy...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/BF03256918

    authors: Witthaut J,Bushmakin AG,Gerber RA,Cappelleri JC,Le Graverand-Gastineau MP

    更新日期:2011-11-01 00:00:00

  • Safety, Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic Fibrosis.

    abstract:BACKGROUND:Among the many consequences of loss of CFTR protein function, a significant reduction of the secretion of bicarbonate (HCO3-) in cystic fibrosis (CF) is a major pathogenic feature. Loss of HCO3- leads to abnormally low pH and impaired mucus clearance in airways and other exocrine organs, which suggests that ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-019-00861-x

    authors: Gomez CCS,Parazzi PLF,Clinckspoor KJ,Mauch RM,Pessine FBT,Levy CE,Peixoto AO,Ribeiro MÂGO,Ribeiro AF,Conrad D,Quinton PM,Marson FAL,Ribeiro JD

    更新日期:2020-02-01 00:00:00

  • Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis : A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial.

    abstract:OBJECTIVE:To evaluate the efficacy and safety of the natural platelet-activating factor receptor antagonist, BN 52021 (ginkgolide B) in the treatment of patients with severe sepsis related to Gram-negative and mixed bacterial infection. DESIGN AND SETTING:Prospective, randomised, double-blind, placebo-controlled, mult...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200424030-00002

    authors: Albrecht DM,van Ackern K,Bender HJ,Hof H,Kox W,Victor N,Funk P,Kieser M,Köhler S,Krausch D,Marzi I,Menges T,Schmidt H

    更新日期:2004-01-01 00:00:00

  • Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.

    abstract:OBJECTIVE:To estimate the cost effectiveness of venlafaxine compared with generic fluoxetine and generic amitriptyline used in major depressive disorder in primary care in the UK. METHODS:A decision-tree model for the treatment of major depressive disorder was constructed using a Delphi panel. The tree was populated w...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200929030-00004

    authors: Lenox-Smith A,Greenstreet L,Burslem K,Knight C

    更新日期:2009-01-01 00:00:00

  • Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.

    abstract:BACKGROUND AND OBJECTIVE:The degree of cycle control achieved with a hormonal contraceptive method is an important determinant of its acceptance and continuation. This study set out to compare the cycle control and bleeding profile of drospirenone (DRSP) 3 mg/ethinylestradiol (EE) 20 μg in a 24-active pill/4-inert pill...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章,meta分析,多中心研究

    doi:10.2165/11590260-000000000-00000

    authors: Anttila L,Neunteufel W,Petraglia F,Marr J,Kunz M

    更新日期:2011-01-01 00:00:00

  • Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review.

    abstract:BACKGROUND:Warfarin is a commonly used oral anticoagulant and its interaction with other drugs can result in serious thrombotic or bleeding events. Currently, there is no definitive evidence on the possibility of an interaction between warfarin and oseltamivir. OBJECTIVE:The objective of this study was to investigate ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11595860-000000000-00000

    authors: Lee SH,Kang HR,Jung JW,Kwon JW,Hong KS,Yu KS,Cho SH

    更新日期:2012-02-01 00:00:00

  • Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.

    abstract:BACKGROUND AND OBJECTIVE:Concerns that antiepileptic brand-to-generic interchange results in disruption of seizure control are widespread. The objective of this study was to evaluate the safety and tolerability of the brand-to-generic levetiracetam switch in patients with focal or generalized epilepsy. METHODS:A prosp...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0351-1

    authors: Vari MS,Pinto F,Mencaroni E,Giudizioso G,Minetti C,La Neve A,Francavilla T,Piccioli M,Striano S,del Gaudio L,Tovo P,Striano P,Verrotti A

    更新日期:2016-01-01 00:00:00

  • Amlodipine in ischaemic left ventricular dysfunction with mild to moderate heart failure.

    abstract:OBJECTIVE:In this study, we evaluated the effectiveness of amlodipine in patients with severe ischaemic left ventricular dysfunction (LVD) and mild to moderate heart failure, but not current angina, assessing the effects of the drug on symptoms, left ventricular function and exercise capacity. PATIENTS AND METHODS:We ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199816040-00003

    authors: Perna GP,Valle G,Cianfrone N,Luca GD,Amico C,Coli C

    更新日期:1998-01-01 00:00:00

  • Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.

    abstract::Mecapegfilgrastim (HHPG-19K) is a long-acting pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) that is administered subcutaneously as prophylaxis once per chemotherapy cycle as a weight-adjusted dose of 100 µg/kg or as a 6 mg fixed dose. It is approved in China to reduce the incidence of inf...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-019-00836-y

    authors: Al-Salama ZT,Keam SJ

    更新日期:2019-10-01 00:00:00

  • Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China.

    abstract:OBJECTIVE:This open, prospective, non-interventional, non-randomised, multi-centre postmarketing surveillance study was conducted over a mean period of 13.9 weeks to assess the efficacy, safety and acceptance of acarbose in Chinese patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance (IGT...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究

    doi:10.2165/00044011-200727060-00003

    authors: Pan CY,Landen H

    更新日期:2007-01-01 00:00:00

  • Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.

    abstract:BACKGROUND AND OBJECTIVES:Cancer pain affects patients at all stages of the disease and there are clear guidelines for its management. Morphine is considered the first-choice strong opioid in the treatment of moderate-to-severe pain; however, numerous studies have shown that oxycodone controlled-release (CR) has a simi...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2165/00044011-200828070-00001

    authors: Silvestri B,Bandieri E,Del Prete S,Ianniello GP,Micheletto G,Dambrosio M,Sabbatini G,Endrizzi L,Marra A,Aitini E,Calorio A,Garetto F,Nastasi G,Piantedosi F,Sidoti V,Spanu P

    更新日期:2008-01-01 00:00:00

  • Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

    abstract::Page 806, column 1, line 3: The text, which previously read. ...

    journal_title:Clinical drug investigation

    pub_type: 已发布勘误

    doi:10.1007/s40261-020-00892-9

    authors: Lyseng-Williamson KA

    更新日期:2020-03-01 00:00:00

  • Consumption and distribution of propofol in anaesthesia and intensive care use in Finland.

    abstract:BACKGROUND:Propofol is approved both for anaesthesia and sedation during intensive care. Serious adverse reactions with propofol have recently been reported, but patient exposure to the drug is unknown. OBJECTIVE:To investigate the consumption of propofol in Finnish hospitals and to develop a denominator to estimate p...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200323010-00003

    authors: Kokki H,Närhi U

    更新日期:2003-01-01 00:00:00

  • Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteers.

    abstract:BACKGROUND AND OBJECTIVES:Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract. DA-6034 has been shown to be effective in an IBD model and has demonstrated a good toxicological profile in preclinical studies. This study evaluated the tolerability, safety and pharmacokinetics...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-013-0147-0

    authors: Lee J,Shin KH,Kim JR,Lim KS,Jang IJ,Chung JY

    更新日期:2014-01-01 00:00:00

  • Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.

    abstract:BACKGROUND AND OBJECTIVES:Dasotraline is a novel inhibitor of dopamine and norepinephrine reuptake currently being investigated in clinical studies for the treatment of attention-deficit/hyperactivity disorder (ADHD). Uniquely, relative to current ADHD medications, dasotraline has a slow absorption and long elimination...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0358-7

    authors: Hopkins SC,Sunkaraneni S,Skende E,Hing J,Passarell JA,Loebel A,Koblan KS

    更新日期:2016-02-01 00:00:00

  • Hypokalaemia in healthy volunteers after single and multiple doses of formoterol or salbutamol.

    abstract::A specific beta(2)-adrenoceptor-mediated effect, hypokalaemia, was studied in healthy volunteers after single as well as multiple dosages of the long-acting agonist formoterol and the short-acting agent salbutamol. The purpose of the study was to test with simple methodologies if rapidly induced tachyphylaxis for this...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199815060-00009

    authors: van den Berg BT,Louwerse RT,Luiken GJ,Jonkers RE,van Boxtel CJ

    更新日期:1998-01-01 00:00:00

  • Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.

    abstract::Doravirine (MK-1439) is a novel non-nucleoside reverse transcriptase inhibitor indicated for the combination treatment of human immunodeficiency virus type-1 (HIV-1) infection. The recommended dose is 100 mg once daily. This review summarizes the pharmacokinetics of doravirine, the influence of intrinsic factors, and ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-020-00934-2

    authors: Khalilieh S,Yee KL,Sanchez R,Stoch SA,Wenning L,Iwamoto M

    更新日期:2020-10-01 00:00:00

  • The effect of active vitamin D administration on muscle mass in hemodialysis patients.

    abstract:BACKGROUND:Muscle wasting is common and insidious in end-stage renal disease (ESRD). Loss of muscle quantity and quality reduces quality of life and increases mortality in ESRD patients. Additionally, secondary hyperparathyroidism (SHPT) causes muscle atrophy. Meanwhile, vitamin D, which is used for SHPT treatment, pla...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-013-0132-7

    authors: Mori A,Nishino T,Obata Y,Nakazawa M,Hirose M,Yamashita H,Uramatsu T,Shinzato K,Kohno S

    更新日期:2013-11-01 00:00:00

  • Regression and Genomic Analyses on the Association Between Dose-Normalized Mycophenolic Acid Exposure and Absolute Neutrophil Count in Steroid-Free, De Novo Kidney Transplant Recipients.

    abstract:BACKGROUND AND OBJECTIVES:The hematological side effects associated with mycophenolic acid (MPA) are relatively common and have severe consequences. The majority of literature data have not shown clear consistency in the MPA exposure-neutropenia relationship. We hypothesized that (i) adult de novo kidney transplant rec...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0694-5

    authors: Kiang TKL,Partovi N,Shapiro RJ,Berman JM,Collier AC,Ensom MHH

    更新日期:2018-11-01 00:00:00

  • Severe INR elevation in a patient with choledocholithiasis receiving cefoperazone.

    abstract::Cefoperazone is a third-generation cefalosporin that contains the N-methyl- thio-tetrazole (NMTT) side chain, which inhibits vitamin K-dependent carboxylation. Administration of NMTT-containing cefalosporins can cause alterations in the hepatic glutathione redox state, resulting in a dose-related increase in oxidised ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200626080-00006

    authors: Alagozlu H,Cindoruk M,Unal S

    更新日期:2006-01-01 00:00:00

  • Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases.

    abstract::A pharmacokinetic study was carried out in patients with unresectable colorectal liver metastases who had primarily been included in a phase II trial of intra-arterial cisplatin (DDP) plus intravenous fluorouracil. Ten patients of those accrued for the clinical study underwent the pharmacokinetic investigation upon li...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199612020-00005

    authors: Civalleri D,Esposito M,De Cain F,Balletto N,Mondini G,Gogioso L,Viale M,Vannozzi MO

    更新日期:1996-08-01 00:00:00

  • Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.

    abstract:OBJECTIVE:The objective of this study was to evaluate the long-term cost effectiveness of exenatide once weekly (ExQW) versus insulin glargine (IG) or liraglutide 1.2 mg (Lira1.2mg) for the treatment of adult patients with type 2 diabetes mellitus (T2DM) not adequately controlled on oral antidiabetic drug (OAD) therapy...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-017-0586-0

    authors: Tzanetakos C,Bargiota A,Kourlaba G,Gourzoulidis G,Maniadakis N

    更新日期:2018-01-01 00:00:00

  • Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children.

    abstract::Since the introduction of the first gadolinium-based contrast agent (GBCA) approximately 25 years ago, magnetic resonance imaging (MRI) using GBCAs has revolutionized diagnostic and follow-up imaging of pathological lesions, with clinical applications expanded to encompass almost all fields of medicine. Intravenous ga...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-013-0066-0

    authors: Scott LJ

    更新日期:2013-04-01 00:00:00

  • Observational study of intravenous lacosamide in patients with convulsive versus non-convulsive status epilepticus.

    abstract:BACKGROUND AND OBJECTIVES:Status epilepticus (SE) is an important emergency situation associated with high morbidity and mortality. The goal of pharmacological therapy-rapid seizure termination-is only achieved in just over half of patients with first-line anti-epileptic drug (AED) therapy and many patients require sec...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0295-5

    authors: Moreno Morales EY,Fernandez Peleteiro M,Bondy Peña EC,Domínguez Lorenzo JM,Pardellas Santiago E,Fernández A

    更新日期:2015-07-01 00:00:00

  • Amlexanox for the treatment of recurrent aphthous ulcers.

    abstract::Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population. The minor manifestation of the condition is the most common and is characterised by small, shallow, round or oval lesions that are surrounded by a raised erythematous h...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200525090-00001

    authors: Bell J

    更新日期:2005-01-01 00:00:00

  • Immediate neurological recovery following perispinal etanercept years after brain injury.

    abstract::Positron emission tomographic brain imaging and pathological examination have revealed that a chronic, intracerebral neuroinflammatory response lasting for years after a single brain injury may occur in humans. Evidence suggests the immune signaling molecule, tumor necrosis factor (TNF), is centrally involved in this ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-014-0186-1

    authors: Tobinick E,Rodriguez-Romanacce H,Levine A,Ignatowski TA,Spengler RN

    更新日期:2014-05-01 00:00:00

  • Ambroxol lozenge bioavailability : an open-label, two-way crossover study of the comparative bioavailability of ambroxol lozenges and commercial tablets in healthy thai volunteers.

    abstract:OBJECTIVE:To compare the bioavailability of two 15mg ambroxol lozenges with a commercial 30mg ambroxol tablet. DESIGN:Open-label, two-way crossover study. METHOD:Each formulation was randomly administered to 20 healthy Thai volunteers (ten male and ten female) with a 1-week washout period between formulations. After ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200323040-00007

    authors: Rojpibulstit M,Kasiwong S,Juthong S,Phadoongsombat N,Faroongsarng D

    更新日期:2003-01-01 00:00:00

  • Pantoprazole: a proton pump inhibitor.

    abstract::Pantoprazole is a proton pump inhibitor (PPI) that binds irreversibly and specifically to the proton pump, thereby reducing gastric acid secretion. Pantoprazole has a relatively long duration of action compared with other PPIs, and a lower propensity to become activated in slightly acidic body compartments. To date, n...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/1153121-S0-000000000-00000

    authors: Moreira Dias L

    更新日期:2009-01-01 00:00:00

  • Barriers to pain management: focus on opioid therapy.

    abstract::Despite the availability of effective pain treatments, there are numerous barriers to effective management resulting in a large proportion of patients not achieving optimal pain control. Chronic pain is inadequately treated because of a combination of cultural, societal, educational, political and religious constraint...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/11630040-000000000-00000

    authors: Zuccaro SM,Vellucci R,Sarzi-Puttini P,Cherubino P,Labianca R,Fornasari D

    更新日期:2012-02-22 00:00:00

  • Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study.

    abstract:BACKGROUND AND OBJECTIVES:Hypertension, one of the major treatable cardiovascular (CV) risk factors, usually occurs in association with other major risk factors. As well as providing rapid blood pressure (BP) goal attainment, antihypertensive therapy should also provide reductions in CV events and mortality in a wide r...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2165/00044011-200828110-00001

    authors: Ogilvie RI,Anand S,Roy P,De Souza S,PEACH investigators.

    更新日期:2008-01-01 00:00:00